No OS Boost With Palbociclib and Endocrine Therapy in Premenopausal Breast Cancer

(MedPage Today) -- No improvement in overall survival (OS) was observed with palbociclib (Verzenio) plus endocrine therapy versus capecitabine in premenopausal patients with hormone receptor-positive, HER2-negative metastatic breast cancer, according...